Stoke Therapeutics Past Earnings Performance
Past criteria checks 0/6
Stoke Therapeutics's earnings have been declining at an average annual rate of -32%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 75.2% per year.
Key information
-32.0%
Earnings growth rate
46.4%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 75.2% |
| Return on equity | -65.6% |
| Net Margin | -1,192.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Stoke Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 9 | -105 | 41 | 82 |
| 30 Sep 23 | 9 | -103 | 40 | 82 |
| 30 Jun 23 | 9 | -105 | 40 | 81 |
| 31 Mar 23 | 15 | -99 | 40 | 79 |
| 31 Dec 22 | 12 | -101 | 39 | 78 |
| 30 Sep 22 | 9 | -100 | 38 | 73 |
| 30 Jun 22 | 6 | -96 | 37 | 67 |
| 31 Mar 22 | 3 | -94 | 34 | 63 |
| 31 Dec 21 | 0 | -86 | 32 | 54 |
| 30 Sep 21 | 0 | -76 | 29 | 47 |
| 30 Jun 21 | 0 | -67 | 26 | 41 |
| 31 Mar 21 | 0 | -58 | 23 | 35 |
| 31 Dec 20 | 0 | -52 | 21 | 32 |
| 30 Sep 20 | 0 | -48 | 19 | 30 |
| 30 Jun 20 | 0 | -43 | 17 | 29 |
| 31 Mar 20 | 0 | -38 | 14 | 27 |
| 31 Dec 19 | 0 | -32 | 12 | 24 |
| 30 Sep 19 | 0 | -26 | 9 | 20 |
| 30 Jun 19 | 0 | -21 | 7 | 15 |
| 31 Mar 19 | 0 | -16 | 6 | 11 |
| 31 Dec 18 | 0 | -13 | 4 | 8 |
Quality Earnings: 0GT is currently unprofitable.
Growing Profit Margin: 0GT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0GT is unprofitable, and losses have increased over the past 5 years at a rate of 32% per year.
Accelerating Growth: Unable to compare 0GT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0GT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.7%).
Return on Equity
High ROE: 0GT has a negative Return on Equity (-65.62%), as it is currently unprofitable.